Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 4,113 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions: XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablets, single dose, Zyrtec® 10 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Heart Failure
Interventions: Telehealth monitoring; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Refractive Error, Myopia
Interventions: Verofilcon A contact lenses, Etafilcon A contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 2 more

Conditions: Interstitial Lung Disease
Interventions: EBUS without stylet; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gulf War Syndrome
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Orange, New Jersey

Conditions: Graft Versus Host Disease
Interventions: Tacrolimus, Methotrexate, Bortezomib, Sirolimus; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: Imprime PGG, MK-3475; Drug
Lead sponsor: Lawrence Feldman, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more

Conditions: Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Fluid Balance, Cognitive Performance
Interventions: TP1, TP2, Placebo; Other
Lead sponsor: Liquid I.V.; Other
Eligibility: 18 Years to 49 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GW433908, ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 4 Weeks to 2 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2022
U.S. locations: 2
States / cities: Jacksonville, Florida • Durham, North Carolina

Conditions: Stroke
Interventions: High intensity gait training in Movement Amplification Environment, High intensity gait training in natural environment; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neurocognitive Improvement
Interventions: Citicoline, Microcrystalline Cellulose; Drug · Other
Lead sponsor: Deborah Yurgelun-Todd; Other
Eligibility: 13 Years to 18 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Leukemia, MDS
Interventions: Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant; Radiation · Drug · Device + 1 more
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Interventions: SEARCH algorithm; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Fresno, California • Irvine, California • Los Angeles, California + 5 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Ixabepilone, Capecitabine, Motesanib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: EVG, RTV, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Not listed
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 47
States / cities: Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more

Conditions: Superficial Bladder Cancer
Interventions: BC-819/PEI; Biological
Lead sponsor: Anchiano Therapeutics Israel Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cirrhosis of the Liver
Interventions: SB-1121(1), SB-1121(2); Drug
Lead sponsor: Nguyen Thi Trieu, MD; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Alopecia, Male Pattern Hair Loss
Interventions: KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more

Conditions: Knee Replacement
Interventions: Phone Coaching, Progress reports to providers, 'Hear from Others' Videos, Individualized Feedback, Online exercise program; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Meibomian Gland Dysfunction
Interventions: CBT-008; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Alzheimer's Disease
Interventions: Experimental Bapineuzumab; Drug
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 28
States / cities: Tucson, Arizona • La Habra, California • Lomita, California + 24 more

Search by objective public record fields.

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions

Testing the Effects of Telehealth Monitoring on Rehospitalization and Self Care for Heart Failure Patients in Home Care

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 1

Stylet vs No Stylet During EBUS TBNA

Telemedicine Treatment for Veterans With Gulf War Illness

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Clinical Trial to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

Stroke Training to Advance Balance During Locomotor Experiences (STABLE) Trial

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Optimizing a Remote-based Physical Activity Intervention for Adults With Total Knee Replacement

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease